Trial Profile
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Apr 2011 Planned end date changed from 1 Jun 2010 to 1 Jun 2014 as reported by ClinicalTrials.gov.